VANCOUVER, BC, Feb. 25, 2021 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a leader in the development of psilocybin and other psychedelic compounds with broad cognitive, behavioral, and peripheral physiologic effects, has received approval for its first clinical program in Autism Spectrum Disorder (ASD). The Company has obtained…


Previous articleMarkets for Feb 24: $AION -18.75%, $TRIP +12.64%, $MCUR +11.53%
Next articleRed Light Holland iMicrodose Pack Receives Authorization for the First Legal Import and Sale of Psilocybin Truffles to Brazil